Join
Live feed
·
PRReleasevia Quantisnow
Kalaris Therapeutics Inc. logo

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

ByQuantisnow·Wall Street's wire, on your screen.
KLRS· Kalaris Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KLRS (Kalaris Therapeutics Inc.) and more on Quantisnow.